Insights into the Use of Peripherally Acting µ-Opioid Receptor Antagonists (PAMORAs) in Oncologic Patients: from Scientific Evidence to Real Clinical Practice


Por: Fernandez-Montes, A, de Velasco, G, Aguin, S, Farriols, C, Guirado-Risueno, M, Jerviz-Guia, V, Baeza-Nadal, M, Chicas-Sett, R, Firvida, J, Garcia-Navalon, F, Martin, P, Perezagua-Marin, C, Rodriguez, D, Santamaria, J, Sauri, T and Cobo, M

Publicada: 1 mar 2021 Ahead of Print: 26 feb 2021
Resumen:
Opinion statement Management of chronic pain is crucial to improve the quality of life of cancer and palliative care patients. Opioid-based treatments used to control pain can be prolonged over time. Unfortunately, constipation is one of the most disturbing adverse effects of long-term use of opioids. Opioid-induced constipation (OIC) occurs when opioids bind to the specific receptors present in the gastrointestinal (GI) tract, and can affect any patients receiving chronic opioid therapy, including cancer patients. The limited efficacy of laxatives to treat OIC symptoms prompted the search for new therapeutic strategies. Peripherally acting mu-opioid receptor antagonists (PAMORAs) have recently emerged as new effective drugs for OIC management due to their specific binding to enteric mu-receptors. Little information is available on the use of PAMORAs in real-life practice for OIC treatment in cancer patients. In this paper, a panel of experts specializing in cancer and palliative care pools their clinical experience with PAMORAs in cancer patients presenting OIC and highlights the importance of timing and choice of therapy in achieving prompt OIC management and benefitting patients.

Filiaciones:
Fernandez-Montes, A:
 Complexo Hosp Ourense, Med Oncol, Ramon Puga 54, Orense 32003, Spain

de Velasco, G:
 Hosp Univ 12 Octubre, Medicat Oncol, Madrid, Spain

Aguin, S:
 Complejo Hosp Univ Santiago de Composteta, Med Oncol, La Coruna, Spain

Farriols, C:
 Hosp del Mar, Palliat Care Unit, Barcelona, Spain

:
 Hosp Gen Univ Elche, Med Oncol, Alicante, Spain

Jerviz-Guia, V:
 Hosp Univ Clin San Cecilio, Oncol Radiotherapy Unit, Granada, Spain

Baeza-Nadal, M:
 Complejo Hosp Univ, Palliat Unit Care, Toledo, Spain

Chicas-Sett, R:
 Hosp Univ Doctor Negrin, Radiat Oncol, Las Palmas Gran Canaria, Spain

Firvida, J:
 Hosp Cosaga, Med Oncol, Orense, Spain

Garcia-Navalon, F:
 Hosp Univ Son Llatzer, Med Oncol, Palma De Mallorca, Spain

:
 Hosp Marina Baixa Villajoyosa, Med Oncol, Alicante, Spain

Perezagua-Marin, C:
 Hosp Henares, Med Oncol, Madrid, Spain

Rodriguez, D:
 Hosp Univ St Joan de Reus, Palliat Care Unit, Tarragona, Spain

Santamaria, J:
 Hosp Univ Son Espases, Palliat Care Unit, Palma De Mallorca, Islas Baleares, Spain

Sauri, T:
 Hosp Clin Barcelona, Med Oncol, Barcelona, Spain

 IDIBAPS, Tianslat Genom & Targeted Therapeut Solid Tumors, Barcelona, Spain

Cobo, M:
 Hosp Univ Reg & Virgen de la Victoria, IBIMA, Med Oncol, Malaga, Spain
ISSN: 15272729





Current Treatment Options in Oncology
Editorial
Current Science Inc., ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES, Estados Unidos America
Tipo de documento: Review
Volumen: 22 Número: 3
Páginas: 26-26
WOS Id: 000622321600001
ID de PubMed: 33635493

MÉTRICAS